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Abstract
Background: The impact of skin invasion in node negative breast cancer is uncertain.
Methods: We determined the prognosis in 97 node negative breast cancer patients (case group)
who had tumors with skin invasion. Then we compared these patients with 4500 node negative
invasive breast cancer patients treated surgically in the same period.
Results: Patients with skin invasion tended to be older, had more invasive lobular carcinoma and
larger tumor size, and were less likely to have breast conserving surgery than those in the control
group. The 5-year disease-free survival rate in the case group was 94.0%. There was no significant
difference in the 10-year disease-specific overall survival rates in terms of skin invasion in node
negative patients (90.7% in the case group, 92.9% in the control group; p = 0.2032).
Conclusion: Results suggest that skin invasion has no impact on survival in node negative invasive
breast cancer patients. The adjuvant regimens which the individual institute applies for node
negative breast cancer should be used regardless of skin invasion.
Background
It is well known that the number of metastatic lymph
nodes is closely associated with the prognosis of breast
cancer patients[1,2]. However, some node-negative breast
cancer patients, who are believed to have good prognosis,
experience recurrent disease. Therefore, it is important to
know the prognostic factors in node-negative breast can-
cer patients.
Skin invasion is one of the classical pathological factors
that is associated with prognosis [3]. The T4b category,
according to the TNM classification, includes tumors with
edema, ulcers, and satellite skin nodules that are signs
related to skin invasion of the cancerous lesions[4]. In
usual clinical practice, we sometimes encounter his-
topathological skin invasion in node negative breast can-
cer patients. However there are few reports concerning
this issue. In this article, we investigate the significance of
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skin invasion as a prognostic factor in node negative
breast cancer patients.
Patients and methods
From 1983 to 1999, 8013 patients who had surgical treat-
ment for breast cancer were registered in our institute
database. Among these cases, we looked for breast cancer
patients fulfilling the following requirements: skin inva-
sion determined histopathologically, node negative dis-
ease, no distant metastasis, no primary chemotherapy and
curative treatment. Cases of synchronous bilateral breast
cancer were excluded from this study. There were 97
patients who met all these criteria. Then, we studied these
patients in terms of demography, clinical and pathologi-
cal tumor characteristics, and prognosis.
Because this study is retrospective, accurate information
on survival status, especially survival with recurrence, is
difficult to obtain. However, we could obtain long-term
results of survival or death. Furthermore, we could obtain
the etiology of death. Therefore, we plotted the survival
curve based on disease-specific overall survival using the
Kaplan-Meier method. Only death caused by breast cancer
was considered. Those who died from other causes, as
well as the survival cases, were considered censored cases.
As a control group, we used all node negative invasive
breast cancer patients treated surgically during the same
period. A total of 4567 cases were found in our database.
The number of resected lymph nodes is closely associated
with the accuracy of the determination of node-negativity
[5]. Therefore, 67 patients with five or fewer resected
lymph nodes were excluded from the study. As a result, we
analyzed the data for 4500 patients for the control group.
We studied these patients in terms of demography, clini-
cal and pathological tumor characteristics, and prognosis.
The overall survival curve of this group was plotted as
described above. In order to compare baseline characteris-
tics and treatment types between the case and control
groups, Student's t test was used for age, tumor size, and
the number of resected lymph nodes. A chi square test was
also used for comparison of other factors. The comparison
of groups in terms of survival was made with the log rank
test. Statistical significance of a two-sided test was defined
as a p-value less then 0.05. The SPSS 11.0 software pack-
age was used for these calculations.
Results
The baseline characteristics of 97 cases with node negative
skin invasion are shown in Table 1. The 97 patients
included 96 women and one man. The mean age was 58.8
(range: 30–86). The mean size of tumor was 3.0 cm
(range: 0.8–13.0 cm). Although the histological subtypes
varied significantly, cases of invasive ductal carcinoma (77
cases, 79.4%) were prominent. Forty-nine cases (50.5%)
had estrogen receptor positive disease, 30 cases (30.9%)
had estrogen receptor negative disease, and 18 cases
(18.6%) were in the receptor unknown group. Clinical
evaluation of the skin overlying the tumor is summarized
in Table 2. Most cases had signs in the overlying skin.
However, 4 cases (4.1%) could not be evaluated for skin
involvement preoperatively. The type of surgical treat-
ment and post-operative treatment is summarized in
Table 3. Because these cases occurred several years ago, 90
cases (92.8%) had total mastectomy. All cases had axillary
resection, and the median number of removed lymph
nodes was 22 (Range; 5 to 70). Twenty-eight cases had
chemotherapy, such as cyclophosphamide, methotrexate,
and fluorouracil, or the oral derivatives of fluorouracil.
Forty patients (41.2%) had endocrine therapy. All of them
were given tamoxifen. Radiation therapy was given to 3
(3.1%) patients.
Table 1: Demography and tumor characteristics
Case Control
Gender Female 96 (99.0%) 4485 (99.7%) p = 0.290
Male 1 (1.0%) 15 (0.3%)
Age Mean 58.8 52.8 p < 0.001
Range 30–86 23–91
Tumor size (cm) Median 3 2.2 p < 0.001
Range 0.8–13.0 0–20
Nodal status Node Negative 97 (100%) 4500 (100%)
Node Positive 0 (0%) 0 (0%)
Histological subtype Invasive ductal 77 (79.4%) 3941 (87.6%) p = 0.002
Invasive lobular 12 (12.4%) 194 (4.3%)
Mucinous 5 (5.2%) 216 (4.8%)
Other 3 (3.1%) 145 (3.3%)
Estrogen receptor Positive 49 (50.5%) 1608 (35.7%) p < 0.001
Status Negative 30 (30.9%) 1132 (25.2%)
Unknown 18 (18.6%) 1760 (39.1%)World Journal of Surgical Oncology 2008, 6:10 http://www.wjso.com/content/6/1/10
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For the control group, the baseline characteristics and
treatment types are listed in Tables 1 and 3, respectively.
Gender, the number of resected lymph nodes, chemother-
apy, and endocrine therapy were not significantly differ-
ent between groups. On the other hand, older patients,
larger tumor size, more histological subtypes of invasive
lobular carcinoma, more unknown receptor status, and
more partial mastectomies were observed for the case
group with statistical significance.
The disease-free survival curve of these 97 patients is
shown in Figure 1. The 5-year disease-free survival rate
was 94.0%, with a median follow up of 90 months. The
90-month disease-free survival rate was 84.0%. The dis-
ease-specific overall survival of these 97 patients is com-
pared with the control group in Figure 2. There was no
significant difference between these 2 groups. The 10-year
overall survival rates were 90.7% in the case group and
92.9% in the control group (p = 0.2032). The median fol-
low up times were 118 months in the case group and 116
months in the control group.
Discussion
This study demonstrates that skin-involving node nega-
tive breast cancer patients had a 5-year disease-free sur-
vival rate of 94.0% and a 10-year disease-specific overall
survival rate of 90.7%. The latter figure was comparable
with that of overall node negative breast cancer patients
(92.9%, p = 0.2032). These results suggest that skin inva-
sion has no effect on survival in node negative breast can-
cer patients.
There were some differences in tumor characteristics and
treatment type between the case and the control groups.
The mean tumor size in the case group was larger than
that in the control group. This fact means that there was
less frequent breast-conserving surgery, and more fre-
quent unknown receptor status in the case group. Previ-
ously, the receptor status was determined based on
enzyme immunoassay (EIA). Because EIA requires a fresh
sample of tumor, receptor status tends to be unknown
when the cancerous lesion is too small.
Invasive lobular carcinoma was more common in the case
group. The patients with this subtype of breast cancer
tended to be older, have a larger tumor size, and have a
lower rate of lymph node involvement [6]. These charac-
teristics might contribute to the differences between the
case and the control groups in our study. Although all
these differences have to be taken into consideration, we
believe that these disparities do not affect the survival
analysis significantly.
The nodal status is the most reliable prognostic factor, and
a negative node finding is associated with the most favo-
rable prognosis. However, distant metastasis can develop
even in these node negative patient groups. Therefore, we
have to seek other reliable prognostic factors independent
of nodal status.
The significance of skin invasion in node negative breast
cancer is uncertain. Tumors with signs of skin invasion,
Table 2: Clinical findings in skin in the ipsilateral breast
Dimpling 34 (35.1%)
Tumor fixing to the skin 30 (30.9%)
Nipple retraction 15 (15.5%)
Ulcer 6 (6.2%)
Edema 1 (1.0%)
Post biopsy 3 (3.1%)
No abnormal findings 4 (4.1%)
Table 3: Treatment
Case Control
Operation Total mastectomy 90 (92.8%) 3504 (77.9%) p < 0.001
Partial mastectomy 7 (7.2%) 963 (21.4%)
Unknown 0 (0%) 33 (0.7%)
Number of removed Median 22 22 p = 0.630
lymph nodes Range 5–70 5–125
Chemotherapy Yes 28 (30.0%) 1051 (23.4%) p = 0.127
No 69 (70.0%) 3449 (76.6%)
Endocrine Yes 40 (41.2%) 1591 (35.4%) p = 0.138
therapy No 57 (58.8%) 2909 (64.6%)
Radiation therapy Yes 3 (3.1%) 359 (8.0%) p = 0.081
No 93 (96.9%) 4141 (92.0%)World Journal of Surgical Oncology 2008, 6:10 http://www.wjso.com/content/6/1/10
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such as edema, ulcers, and satellite nodules, are classified
as T4 category in TNM classification. Patients with a T4b
tumor are considered as having advanced disease. Further-
more, Perrone et al. reported that skin invasion was one of
the prognostic factors in breast cancer[3]. On the other
hand, it has been reported that skin invasion loses prog-
nostic significance in multivariable analysis, and only nip-
ple invasion has impact on prognosis[7]. Our data suggest
that skin invasion is not a prognostic factor independent
of nodal status.
We accept that our study has limitations. It is a retrospec-
tive study, has a small number of cases, and does not
include strictly T4 tumors. However, we believe that our
findings can guide clinical practice in breast cancer.
Many prognostic factors in breast cancer have been stud-
ied recently. The St. Gallen consensus advocates prognos-
tic factors other than nodal status, such as vascular
involvement, receptor status, nuclear grading, HER2 sta-
tus, and age and size of tumor [8]. Furthermore, recent
advances in molecular biology have led to identification
of biological markers that are associated with biological
activities of the tumors. Gene-expression-profiling studies
[9] including urokinase-type plasminogen activator: plas-
minogen activator inhibitor type-1 complex [10], estro-
gen receptor, progesterone receptor [11], cyclin E [12],
and HER2 [13] are the results of these advances. However,
we believe that classical histopathological evaluation is
still important because of its ubiquitous use and good
cost-benefit balance.
Sometimes skin invasion cannot be predicted preopera-
tively. Based on our findings, dimpling alone can be a clue
for skin invasion. Skin invasion is important for manage-
ment of the overlying skin in the surgical treatment.
Whether in total mastectomy or in breast conserving treat-
ment, complete resection is essential for avoiding the risk
of local recurrence [14]. Removal of overlying skin is nec-
essary when skin invasion is predicted.
Conclusion
Our study suggests that skin invasion has no impact on
survival in node negative invasive breast cancer patients.
The adjuvant regimen which the individual institute
determines for node negative breast cancer should be
applied to skin invasive node negative breast cancer
patients.
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